

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated below as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: 5 March 2001

Typed Name: Carolyn C. Caires

Signature: Carolyn C. Caires



GAU 1644 #
FG0810 US
Box SEQ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Riser and DeNichilo

Title: METHODS FOR DETECTING,
PREVENTING, AND TREATING
RENAL DISORDERS BY
MODULATING, REGULATING, AND
INHIBITING CONNECTIVE TISSUE
GROWTH FACTOR

Confirmation No.: 9469

U.S. Serial No.: 09/392,024

Filing Date: 8 September 1999

Examiner: P. Nolan

Group Art Unit: 1644

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAR 13 2001
TECH CENTER 1600/2900

RECEIVED
MAR 15 2001
TECH CENTER 1600/2900

RESPONSE TO NOTICE TO COMPLY

Sir:

This is in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence, dated 20 December 2000, in the above-referenced case, the accompanying Petition For Extension of Time allowing the Applicants until 20 March 01 to respond. The Notice to Comply stated that the above-referenced application failed to comply with the requirements of 37 C.F.R. 1.821 through 1.825 for not containing a paper copy of the Sequence Listing and because a copy of the Sequence Listing in computer readable form had not been submitted. Accordingly, the following documents accompany this Response:

1. Sequence Listing paper copy (2 pages);
2. Sequence Listing computer readable form copy (1 diskette);

3. Sequence Listing Statement Under 37 C.F.R. 1.821(f) (2 pages);
4. Supplemental Preliminary Amendment (3 pages);
5. Petition for Extension of Time (one-month) (2pages); and
6. Copy of Notice to Comply (1 page).

Applicants submit that this Response and the accompanying documents fully satisfy the requirements of 37 C.F.R. 1.821 through 1.825. If the U.S. Patent and Trademark Office believes otherwise, Applicants respectfully request notice and an opportunity to respond. Please contact Applicants' Attorney with any questions regarding this Response.

The Commissioner is hereby authorized to charge any additional costs necessary for consideration of this Response or credit any overpayment to Deposit Account No. 50-0811. A duplicate of this Response is enclosed.

Respectfully submitted,

Date:

6 March 01



Leanne C. Price, Esq.
Reg. No. 42,090

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco, CA 94080
Main: 650-866-7200
Direct: 650-866-7254
Facsimile: 650-866-7204